Page last updated: 2024-10-31

nevirapine and Malaria

nevirapine has been researched along with Malaria in 14 studies

Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.

Malaria: A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.

Research Excerpts

ExcerptRelevanceReference
" However, there was a high risk of recurrent parasitemia following AL treatment, which was significantly lower in children taking LPV/r-based ART compared with nevirapine-based ART."9.19Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. ( Achan, J; Arinaitwe, E; Charlebois, E; Clark, TD; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, MR; Muhindo, MK; Mwangwa, F; Rosenthal, PJ; Ruel, T; Tappero, JW, 2014)
"Artemisinin-based combination therapies (ACTs) are the primary treatment for malaria."8.31Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. ( Aweeka, F; Ehrlich, H; Freeman, T; French, J; Goodwin, J; Huang, L; Kajubi, R; Kay, K; Li, F; Mwebaza, N; Ou, J; Parikh, S; Riggs, M; Ruiz-Garcia, A; Wade, M; Wang, K, 2023)
"Clinical trials demonstrated intermittent preventive treatment in pregnancy with mefloquine (MQ) reduced malaria rates among pregnant women, yet an unexpected higher risk of mother-to-child transmission (MTCT) of HIV among HIV-positive women receiving MQ has also been observed."7.88Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy. ( Desai, M; Dinh, C; Gonzalez, R; Haaland, RE; Heneine, W; Katana, A; Martin, A; Menendez, C; Otieno, K; Slutsker, L; Williamson, J, 2018)
"We investigated the influence of efavirenz (EFV)- or nevirapine (NVP)-based antiretroviral therapy (ART) on lumefantrine plasma exposure in HIV-malaria-coinfected patients and implication of pharmacogenetic variations."7.83CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. ( Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2016)
"HIV-malaria co-infected patients in most parts of sub-Saharan Africa are treated with both artemether-lumefantrine (AL) and efavirenz (EFV) or nevirapine (NVP)-based antiretroviral therapy (ART)."7.81The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. ( Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)
"In this study the influence of first-line antimalarial drug artemether-lumefantrine on the pharmacokinetics of the antiretroviral drug nevirapine was investigated in the context of selected single nucleotide polymorphisms (SNPs) in a cohort of adult HIV-infected Nigerian patients."5.30Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction? ( Abdullahi, ST; Bakare-Odunola, MT; Bolarinwa, RA; Khoo, S; Olagunju, A; Olarewaju, OJ; Owen, A; Soyinka, JO, 2019)
" However, there was a high risk of recurrent parasitemia following AL treatment, which was significantly lower in children taking LPV/r-based ART compared with nevirapine-based ART."5.19Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. ( Achan, J; Arinaitwe, E; Charlebois, E; Clark, TD; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, MR; Muhindo, MK; Mwangwa, F; Rosenthal, PJ; Ruel, T; Tappero, JW, 2014)
"Artemether-lumefantrine and nevirapine-based antiretroviral therapy (ART) are the most commonly recommended first-line treatments for malaria and HIV, respectively, in Africa."5.15Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. ( Barnes, KI; Cohen, K; Kredo, T; Maartens, G; Mauff, K; Smith, P; Van der Walt, JS; Wiesner, L, 2011)
"Artemisinin-based combination therapies (ACTs) are the primary treatment for malaria."4.31Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. ( Aweeka, F; Ehrlich, H; Freeman, T; French, J; Goodwin, J; Huang, L; Kajubi, R; Kay, K; Li, F; Mwebaza, N; Ou, J; Parikh, S; Riggs, M; Ruiz-Garcia, A; Wade, M; Wang, K, 2023)
"Clinical trials demonstrated intermittent preventive treatment in pregnancy with mefloquine (MQ) reduced malaria rates among pregnant women, yet an unexpected higher risk of mother-to-child transmission (MTCT) of HIV among HIV-positive women receiving MQ has also been observed."3.88Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy. ( Desai, M; Dinh, C; Gonzalez, R; Haaland, RE; Heneine, W; Katana, A; Martin, A; Menendez, C; Otieno, K; Slutsker, L; Williamson, J, 2018)
"We investigated the influence of efavirenz (EFV)- or nevirapine (NVP)-based antiretroviral therapy (ART) on lumefantrine plasma exposure in HIV-malaria-coinfected patients and implication of pharmacogenetic variations."3.83CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. ( Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2016)
"HIV-malaria co-infected patients in most parts of sub-Saharan Africa are treated with both artemether-lumefantrine (AL) and efavirenz (EFV) or nevirapine (NVP)-based antiretroviral therapy (ART)."3.81The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. ( Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)
"Artesunate plus amodiaquine is used for malaria treatment in regions with overlapping HIV endemicity."3.80Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. ( Adedeji, WA; Adewole, IF; Akinola, IT; Akinyinka, OO; Aweeka, FT; Darin, KM; Fehintola, FA; Lindegardh, N; Ma, Q; Morse, GD; Murphy, RL; Ojengbede, O; Parikh, S; Scarsi, KK; Taiwo, B; Tarning, J, 2014)
"This was a prospective, non-randomized, open-label study conducted in Bagamoyo district, with three arms of HIV-infected adults: efavirenz-based treatment arm (EFV-arm) n = 66, nevirapine-based treatment arm (NVP-arm) n = 128, and control-arm n = 75, with uncomplicated malaria."3.80Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy. ( Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngasala, B; Sasi, PG, 2014)
"Co-administration of artemether/lumefantrine with antiretroviral therapy has potential for pharmacokinetic drug interactions."2.77Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ( Back, D; Byakika-Kibwika, P; de Vries, PJ; Hanpithakpong, W; Katabira, E; Khoo, S; Lamorde, M; Lindegardh, N; Mayanja-Kizza, H; Mayito, J; Merry, C; Nabukeera, L; Namakula, R; Ntale, M; Pakker, N; Ryan, M; Tarning, J, 2012)
" However, pharmacokinetic knowledge is lacking for specific populations, especially patients with neglected tropical diseases and severe malnutrition."2.72Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review. ( Beijnen, JH; Dorlo, TPC; Huitema, ADR; Verrest, L; Wilthagen, EA, 2021)
" There were no clinically relevant toxicities nor adverse events in both control and test arms."1.56Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria. ( Abideen, G; Adeniji, H; Adeuja, O; Agbaje, EO; Akanmu, AS; Akinleye, MO; Akinyede, AA; Busari, AW; Hassan, OO; Ken-Owotor, C; Kogbe, S; Ogunfowokan, T; Onwujuobi, AG; Oreagba, IA; Owolabi, ET; Usman, SO, 2020)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's11 (78.57)24.3611
2020's3 (21.43)2.80

Authors

AuthorsStudies
Kay, K1
Goodwin, J1
Ehrlich, H1
Ou, J1
Freeman, T1
Wang, K1
Li, F1
Wade, M1
French, J1
Huang, L1
Aweeka, F1
Mwebaza, N1
Kajubi, R1
Riggs, M1
Ruiz-Garcia, A1
Parikh, S2
Usman, SO1
Oreagba, IA1
Akinyede, AA1
Agbaje, EO1
Akinleye, MO1
Onwujuobi, AG1
Ken-Owotor, C1
Adeuja, O1
Ogunfowokan, T1
Kogbe, S1
Owolabi, ET1
Adeniji, H1
Busari, AW1
Hassan, OO1
Abideen, G1
Akanmu, AS1
Verrest, L1
Wilthagen, EA1
Beijnen, JH1
Huitema, ADR1
Dorlo, TPC1
Haaland, RE1
Otieno, K1
Martin, A1
Katana, A1
Dinh, C1
Slutsker, L1
Menendez, C1
Gonzalez, R1
Williamson, J1
Heneine, W1
Desai, M1
Abdullahi, ST1
Olagunju, A1
Soyinka, JO1
Bolarinwa, RA1
Olarewaju, OJ1
Bakare-Odunola, MT1
Owen, A1
Khoo, S2
Scarsi, KK1
Fehintola, FA1
Ma, Q1
Aweeka, FT1
Darin, KM1
Morse, GD1
Akinola, IT1
Adedeji, WA1
Lindegardh, N2
Tarning, J2
Ojengbede, O1
Adewole, IF1
Taiwo, B1
Murphy, RL1
Akinyinka, OO1
Kakuru, A1
Achan, J1
Muhindo, MK1
Ikilezi, G1
Arinaitwe, E1
Mwangwa, F1
Ruel, T1
Clark, TD1
Charlebois, E1
Rosenthal, PJ1
Havlir, D1
Kamya, MR1
Tappero, JW1
Dorsey, G1
Maganda, BA3
Minzi, OM3
Kamuhabwa, AA3
Ngasala, B1
Sasi, PG1
Ngaimisi, E2
Aklillu, E2
Kredo, T1
Mauff, K1
Van der Walt, JS1
Wiesner, L1
Maartens, G1
Cohen, K1
Smith, P1
Barnes, KI1
Porter, KA2
Cole, SR1
Eron, JJ2
Zheng, Y1
Hughes, MD1
Lockman, S2
Poole, C1
Skinner-Adams, TS2
Hosseinipour, M1
Shaffer, D2
D'Amico, R2
Sawe, FK1
Siika, A2
Stringer, E2
Currier, JS2
Chipato, T2
Salata, R2
McCarthy, JS2
Meshnick, SR2
Butterworth, AS1
Sawe, F1
Hosseinipour, MC1
Byakika-Kibwika, P1
Lamorde, M1
Mayito, J1
Nabukeera, L1
Namakula, R1
Mayanja-Kizza, H1
Katabira, E1
Ntale, M1
Pakker, N1
Ryan, M1
Hanpithakpong, W1
de Vries, PJ1
Back, D1
Merry, C1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Open Label Trial of HIV Protease Inhibitors for the Prevention of Malaria in HIV-Infected Children[NCT00978068]Phase 3176 participants (Actual)Interventional2009-09-30Completed
Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Nevirapine in HIV-infected Adults[NCT00790881]Phase 436 participants (Anticipated)Interventional2008-10-31Completed
Optimal Combination Therapy After Nevirapine Exposure[NCT00089505]Phase 3745 participants (Actual)Interventional2006-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

28-day Risk of Recurrent Parasitemia

To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent parasitemia at 28 days were compared between the two groups. (NCT00978068)
Timeframe: 28 days after antimalarial therapy

InterventionCummulative Risk Percentage (Number)
LPV/r + 2 NRTIs14.0
NVP or EFV + 2 NRTIs40.8

63-day Risk of Recurrent Malaria

To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent malaria at 63 days were compared between the two groups. (NCT00978068)
Timeframe: 28 days after antimalarial therapy

InterventionCumulative Risk Percentage (Number)
LPV/r + 2 NRTIs28.1
NVP or EFV + 2 NRTIs54.2

Estimates of the 6-month Risk of a First Episode of Malaria

To assess the effect of ART independently of potential interactions with antimalarial therapy after treatment for malaria, we compared the two groups with respect to the time to the first episode of malaria. Cumulative risk was estimated using the Kaplan-Meier product-limit formula. (NCT00978068)
Timeframe: Enrollment to 6 months follow up

InterventionCumulative Risk Percentage (Number)
LPV/r + 2 NRTIs40.7
NVP or EFV + 2 NRTIs52.5

Incidence-density of Malaria Defined as the Number of Incident Episodes of Complicated Malaria Per Time at Risk.

(NCT00978068)
Timeframe: Time from randomization to at least 24 months of follow up or until end of the study

InterventionEpisodes/ Person-Yr at Risk (Number)
Group 10.024
Group 20.026

Incidence-density of Malaria Defined as the Number of Incident Episodes of Malaria Per Time at Risk.

(NCT00978068)
Timeframe: Time from randomization to at least 24 months of follow up or until end of the study

InterventionEpisodes/ Person-Yr at Risk (Number)
Group 1: LPV/r + 2 NRTIs1.32
Group 2: Nevirapine (NVP) or Efavirenz (EFV) + 2 NRTIs2.25

Percentage of Uncomplicated Malaria Episodes With Accompanying Adverse Events That Occurred in the 28 Days Following Antimalarial Therapy

The rates of adverse events, defined as severity grade 2 or higher that are possibly, probably or definitely related to study drugs over the course of the 28-day period after antimalarial therapy with artemether-lumefantrine (AL). (NCT00978068)
Timeframe: 28 days after antimalarial therapy

Intervention% uncomplicated malaria episodes w/ AEs (Number)
LPV/r + 2 NRTIs71.0
NVP or EFV + 2 NRTIs79.3

Number of Participants Who Experienced HIV-related Disease Progression or Death

Worsening to WHO stage III/IV (among subjects who had WHO stage I/II at baseline) and death were the composite secondary endpoint. WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents is an approach for use in resource limited settings in studies of progression to symptomatic HIV disease. There are 4 stages of disease staging, 1 being the least severe and 4 being the most severe disease stage based on the HIV related symptoms and diagnoses. Please refer to the following web page for detailed staging criteria: http://www.who.int/docstore/hiv/scaling/anex1.html (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.

Interventionparticipants (Number)
NVP/NVP6
NVP/LPV_r4
NoNVP/NVP19
NoNVP/LPV_r26

Number of Participants Who Experienced Treatment-related Toxicity That Led to Discontinuation of Randomized Regimen.

The outcome is defined as treatment-related toxicity (as evaluated by sites), regardless of grade, that led to discontinuation of randomized regimen. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.

Interventionparticipants (Number)
NVP/NVP15
NVP/LPV_r0
NoNVP/NVP35
NoNVP/LPV_r0

Number of Participants Who Experienced Virologic Failure or Died.

Virologic failure (VF) is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.

Interventionparticipants (Number)
NVP/NVP32
NVP/LPV_r10
NoNVP/NVP42
NoNVP/LPV_r50

Number of Participants Who Received NVP-containing Regimens at Randomization and Experienced NVP-associated Rash or Grade 2+ Liver Lab Abnormality

Any grade of rash or grade 2+ liver lab abnormality events that were claimed to be NVP associated (definitely, probably, or possibly) by site investigators were evaluated. Grade 2+ liver lab abnormality is defined as aspartate aminotransferase (AST)>=2.6 x ULN or alanine aminotransferase (ALT)>=2.6 x ULN. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP arm. Throughout study for NoNVP/NVP arm.

Interventionparticipants (Number)
NVP/NVP20
NoNVP/NVP51

CD4 Count Change From Randomization

Change was calculated as the CD4 count at Week 48 (or at Week 96) minus the baseline CD4 count (last CD4 before/on treatment start date). For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r. Week 48 and 96.

,,,
Interventioncells/mm^3 (Median)
Week 48 CD4 count change from randomizationWeek 96 CD4 count change from randomization
NoNVP/LPV_r172256
NoNVP/NVP172223
NVP/LPV_r201278
NVP/NVP191291

Percent of Participants Who Experienced Virologic Failure or Died

Results report cumulative percent of participants reaching virologic failure (VF) or death by week 48 and week 96 calculated using the Kaplan-Meier method. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.

,,,
InterventionPercent of participants (Number)
week 48 percent of virologic failure or deathweek 96 percent of virologic failure or death
NoNVP/LPV_r1420
NoNVP/NVP1417
NVP/LPV_r412
NVP/NVP2331

Percent of Participants Who Reported to Never Missed Any of the Study Drug Regimen in the Past Month

Self-reported adherence at week 48 and 96 while participants remained on randomized regimen. Adherence interviews for each antiretroviral drug drug the participant is taking was performed by site personnel every 24 weeks. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.

,,,
Interventionpercent of participants (Number)
week 48 percent of full adherence in past monthweek 96 percent of full adherence in past month
NoNVP/LPV_r8687
NoNVP/NVP9093
NVP/LPV_r8895
NVP/NVP8994

Time From Randomization to Virologic Failure or Death for Participants Who Had SD NVP Exposure Prior to Study Entry

5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) with median follow-up 72 weeks and range from 0 to 144 weeks.

,
Interventionweeks (Number)
5th percentile10th percentile25th percentile
NVP/LPV_r6084NA
NVP/NVP121260

Time From Randomization to Virologic Failure or Death for Participants Without SD NVP Exposure Prior to Study Entry

5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Throughout study with median follow-up 72 weeks and range from 0 to 180 weeks.

,
Interventionweeks (Number)
5th percentile10th percentile25th percentile
NoNVP/LPV_r1236132
NoNVP/NVP2436NA

Reviews

1 review available for nevirapine and Malaria

ArticleYear
Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review.
    Clinical pharmacokinetics, 2021, Volume: 60, Issue:9

    Topics: HIV Infections; Humans; Malaria; Malnutrition; Nevirapine; Pharmaceutical Preparations; Poverty

2021

Trials

6 trials available for nevirapine and Malaria

ArticleYear
Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?
    British journal of clinical pharmacology, 2019, Volume: 85, Issue:3

    Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Cross-Over Studies; Cytochrome P-45

2019
Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Aug-01, Volume: 59, Issue:3

    Topics: Antimalarials; Artemisinins; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Female; HI

2014
Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:12

    Topics: Adult; Anti-HIV Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug

2011
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:2

    Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease

2012
The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.
    PloS one, 2012, Volume: 7, Issue:4

    Topics: Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Malaria; Nevirapine; Ritonavir

2012
Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
    The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:9

    Topics: Adult; Alkynes; Anti-HIV Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisin

2012

Other Studies

7 other studies available for nevirapine and Malaria

ArticleYear
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
    Clinical pharmacology and therapeutics, 2023, Volume: 113, Issue:3

    Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Drug Comb

2023
Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria.
    Journal of pharmacological sciences, 2020, Volume: 144, Issue:3

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Be

2020
Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy.
    AIDS research and human retroviruses, 2018, Volume: 34, Issue:11

    Topics: Adult; Anti-HIV Agents; Antimalarials; Cross-Sectional Studies; Drug Interactions; Female; Fetal Blo

2018
Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:5

    Topics: Adolescent; Adult; Amodiaquine; Anti-Retroviral Agents; Antimalarials; Antiretroviral Therapy, Highl

2014
Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy.
    Malaria journal, 2014, May-30, Volume: 13

    Topics: Adult; Africa South of the Sahara; Aged; Alkynes; Anti-Retroviral Agents; Antimalarials; Artemether,

2014
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
    Malaria journal, 2015, Apr-25, Volume: 14

    Topics: Adult; Aged; Alkynes; Anti-Retroviral Agents; Antimalarials; Benzoxazines; Cyclopropanes; Drug Inter

2015
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
    The pharmacogenomics journal, 2016, Volume: 16, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Antimalarials; Artemether; Artemisinins; ATP Binding Cassette Transporter,

2016